Medicinal Cannabis Matters – Friday Roundup 1st November.
Medicinal Cannabis Matters | Friday roundup 1st November 2024.
Medicinal Cannabis Matters – Our weekly round-up of what has been happening in the world of medicinal cannabis this week.
This week, we explore the harmful substances found in recreational cannabis sold on the streets, examine upcoming 2025 trials for medicinal cannabis in treating refractory epilepsy, and we review a new Australian study showing reduced pain and improved mental health.
Today also marks the beginning of Medicinal Cannabis Awareness Week, so stay tuned for Medicann’s campaign updates.
Cannabis sold on the street for recreational use may contain harmful substances.
Cannabis sold on the streets in the UK has been found to contain dangerous levels of mould, yeast, lead, Ecoli and Salmonella. The research was conducted by Manchester Metropolitan University, analysing 60 samples seized by police in Greater Manchester and Northumbria.
Medicinal Cannabis trials for refractory epilepsy to start in 2025.
Two national NHS clinical trials will investigate the safety of CBD and THC in adults and children with treatment-resistant epilepsy. Researchers want to investigate the safety of reducing the number of seizures and how they affect other things such as sleep, behaviour and quality of life.
Patients report reduced pain and improved mental health following a medicinal cannabis treatment.
Chronic pain patients report physical and mental health improvements following their use of medicinal cannabis, according to data published in the Journal of Pain & Palliative Care Pharmacotherapy.
If you’re interested in learning more about medicinal cannabis and how it can help you manage your condition, fill out the simple form linked below. Start your journey today with the only award-winning clinic in Jersey and Guernsey.
Check your eligibility.
https://www.medicann.co.uk/book-consultation/eligibility
Disclaimer:
This blog post and the following featured articles are for information only and any articles on external platforms may be amended at any time. Articles that we refer to in our weekly roundup do not reflect the views of Medicann.
